Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Genitourinary 2Breast 2Tumor-Agnostic 1Plasma cell 1Myeloid 1CNS 1

Conditions

Prostatic Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ranitidine × Genitourinary × Clear all
NCT02441894 2017-01-24

PEGAZUS

Sanofi

Phase 4 Completed
21 enrolled
Genitourinary

Prostatic Neoplasms

NCT00030992 2012-08-20

BMS 247550 to Treat Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
102 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡